Bevacizumab and glioblastomas, a single-centre experience: How disease history and characteristics may affect clinical outcome

Fable Zustovich, Giuseppe Lombardi, Davide Pastorelli, Patrizia Farina, Lara Furini, Renzo Manara, Maurizia Dalla Palma, Antonino Rotilio, Ornella Nicoletto, Vittorina Zagonel

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: In 2009, bevacizumab, a monoclonal antibody to vascular endothelial growth factor, received accelerated approval by the United States Food and Drug Administration for the treatment of glioblastoma, based on its high response rate (RR) and 6-month progression-free survival (PFS-6). However, time to progression and overall survival (OS) were disappointing. Since 2008 have been data collected evaluating the safety and efficacy of bevacizumab in patients with relapsed malignant gliomas. Patients and Methods: This is a retrospective review of adult patients with recurrent malignant gliomas treated with bevacizumab at a dose of 10 mglkg every 14 days; some patients were also treated with irinotecan at a dose of 125 mg/m2 every 14 days. Patients were evaluated for side-effects and clinical outcomes of response, progression and survival. Results: Ten patients received bevacizumab and nine patients received the combination with irinotecan. Both single-agent bevacizumab and combination treatment were well-tolerated. RR was of 28% with no complete responses, PFS-6 was 20% and OS was 4.5 months (95% confidence interval: 3.07-5.98 months). Conclusion: Although well-tolerated, the efficacy of bevacizumab was somewhat disappointing, possibly due to the high rate of secondary high-grade gliomas in the studied patient cohort and the late use of bevacizumab in the course of the disease.

Original languageEnglish
Pages (from-to)5213-5216
Number of pages4
JournalAnticancer Research
Volume30
Issue number12
Publication statusPublished - Dec 2010

Fingerprint

Glioblastoma
irinotecan
Glioma
Survival
Bevacizumab
United States Food and Drug Administration
Vascular Endothelial Growth Factor A
Disease-Free Survival
Monoclonal Antibodies
Confidence Intervals
Safety
Therapeutics

Keywords

  • Chemotherapy
  • Glioma
  • Malignant

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bevacizumab and glioblastomas, a single-centre experience : How disease history and characteristics may affect clinical outcome. / Zustovich, Fable; Lombardi, Giuseppe; Pastorelli, Davide; Farina, Patrizia; Furini, Lara; Manara, Renzo; Palma, Maurizia Dalla; Rotilio, Antonino; Nicoletto, Ornella; Zagonel, Vittorina.

In: Anticancer Research, Vol. 30, No. 12, 12.2010, p. 5213-5216.

Research output: Contribution to journalArticle

Zustovich, F, Lombardi, G, Pastorelli, D, Farina, P, Furini, L, Manara, R, Palma, MD, Rotilio, A, Nicoletto, O & Zagonel, V 2010, 'Bevacizumab and glioblastomas, a single-centre experience: How disease history and characteristics may affect clinical outcome', Anticancer Research, vol. 30, no. 12, pp. 5213-5216.
Zustovich, Fable ; Lombardi, Giuseppe ; Pastorelli, Davide ; Farina, Patrizia ; Furini, Lara ; Manara, Renzo ; Palma, Maurizia Dalla ; Rotilio, Antonino ; Nicoletto, Ornella ; Zagonel, Vittorina. / Bevacizumab and glioblastomas, a single-centre experience : How disease history and characteristics may affect clinical outcome. In: Anticancer Research. 2010 ; Vol. 30, No. 12. pp. 5213-5216.
@article{8b459e609b394938971415d420cfdf0e,
title = "Bevacizumab and glioblastomas, a single-centre experience: How disease history and characteristics may affect clinical outcome",
abstract = "Background: In 2009, bevacizumab, a monoclonal antibody to vascular endothelial growth factor, received accelerated approval by the United States Food and Drug Administration for the treatment of glioblastoma, based on its high response rate (RR) and 6-month progression-free survival (PFS-6). However, time to progression and overall survival (OS) were disappointing. Since 2008 have been data collected evaluating the safety and efficacy of bevacizumab in patients with relapsed malignant gliomas. Patients and Methods: This is a retrospective review of adult patients with recurrent malignant gliomas treated with bevacizumab at a dose of 10 mglkg every 14 days; some patients were also treated with irinotecan at a dose of 125 mg/m2 every 14 days. Patients were evaluated for side-effects and clinical outcomes of response, progression and survival. Results: Ten patients received bevacizumab and nine patients received the combination with irinotecan. Both single-agent bevacizumab and combination treatment were well-tolerated. RR was of 28{\%} with no complete responses, PFS-6 was 20{\%} and OS was 4.5 months (95{\%} confidence interval: 3.07-5.98 months). Conclusion: Although well-tolerated, the efficacy of bevacizumab was somewhat disappointing, possibly due to the high rate of secondary high-grade gliomas in the studied patient cohort and the late use of bevacizumab in the course of the disease.",
keywords = "Chemotherapy, Glioma, Malignant",
author = "Fable Zustovich and Giuseppe Lombardi and Davide Pastorelli and Patrizia Farina and Lara Furini and Renzo Manara and Palma, {Maurizia Dalla} and Antonino Rotilio and Ornella Nicoletto and Vittorina Zagonel",
year = "2010",
month = "12",
language = "English",
volume = "30",
pages = "5213--5216",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Bevacizumab and glioblastomas, a single-centre experience

T2 - How disease history and characteristics may affect clinical outcome

AU - Zustovich, Fable

AU - Lombardi, Giuseppe

AU - Pastorelli, Davide

AU - Farina, Patrizia

AU - Furini, Lara

AU - Manara, Renzo

AU - Palma, Maurizia Dalla

AU - Rotilio, Antonino

AU - Nicoletto, Ornella

AU - Zagonel, Vittorina

PY - 2010/12

Y1 - 2010/12

N2 - Background: In 2009, bevacizumab, a monoclonal antibody to vascular endothelial growth factor, received accelerated approval by the United States Food and Drug Administration for the treatment of glioblastoma, based on its high response rate (RR) and 6-month progression-free survival (PFS-6). However, time to progression and overall survival (OS) were disappointing. Since 2008 have been data collected evaluating the safety and efficacy of bevacizumab in patients with relapsed malignant gliomas. Patients and Methods: This is a retrospective review of adult patients with recurrent malignant gliomas treated with bevacizumab at a dose of 10 mglkg every 14 days; some patients were also treated with irinotecan at a dose of 125 mg/m2 every 14 days. Patients were evaluated for side-effects and clinical outcomes of response, progression and survival. Results: Ten patients received bevacizumab and nine patients received the combination with irinotecan. Both single-agent bevacizumab and combination treatment were well-tolerated. RR was of 28% with no complete responses, PFS-6 was 20% and OS was 4.5 months (95% confidence interval: 3.07-5.98 months). Conclusion: Although well-tolerated, the efficacy of bevacizumab was somewhat disappointing, possibly due to the high rate of secondary high-grade gliomas in the studied patient cohort and the late use of bevacizumab in the course of the disease.

AB - Background: In 2009, bevacizumab, a monoclonal antibody to vascular endothelial growth factor, received accelerated approval by the United States Food and Drug Administration for the treatment of glioblastoma, based on its high response rate (RR) and 6-month progression-free survival (PFS-6). However, time to progression and overall survival (OS) were disappointing. Since 2008 have been data collected evaluating the safety and efficacy of bevacizumab in patients with relapsed malignant gliomas. Patients and Methods: This is a retrospective review of adult patients with recurrent malignant gliomas treated with bevacizumab at a dose of 10 mglkg every 14 days; some patients were also treated with irinotecan at a dose of 125 mg/m2 every 14 days. Patients were evaluated for side-effects and clinical outcomes of response, progression and survival. Results: Ten patients received bevacizumab and nine patients received the combination with irinotecan. Both single-agent bevacizumab and combination treatment were well-tolerated. RR was of 28% with no complete responses, PFS-6 was 20% and OS was 4.5 months (95% confidence interval: 3.07-5.98 months). Conclusion: Although well-tolerated, the efficacy of bevacizumab was somewhat disappointing, possibly due to the high rate of secondary high-grade gliomas in the studied patient cohort and the late use of bevacizumab in the course of the disease.

KW - Chemotherapy

KW - Glioma

KW - Malignant

UR - http://www.scopus.com/inward/record.url?scp=78751519364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751519364&partnerID=8YFLogxK

M3 - Article

C2 - 21187515

AN - SCOPUS:78751519364

VL - 30

SP - 5213

EP - 5216

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -